Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?

被引：0
|
作者：
Luca Prosperini
Giovanna Borriello
Laura De Giglio
Laura Leonardi
Valeria Barletta
Carlo Pozzilli
机构：
[1] S. Andrea Hospital,Multiple Sclerosis Centre, Dept. of Neurology and Psychiatry
[2] Sapienza University,undefined
来源：
BMC Neurology | / 11卷
关键词：
Expand Disability Status Scale; Expand Disability Status Scale Score; Annualise Relapse Rate; Rebif; Disability Progression;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
    Prosperini, Luca
    Borriello, Giovanna
    De Giglio, Laura
    Leonardi, Laura
    Barletta, Valeria
    Pozzilli, Carlo
    BMC NEUROLOGY, 2011, 11
  • [2] Interferon beta in the management of multiple sclerosis
    Pender, MP
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1996, 26 (03): : 343 - 343
  • [3] Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease
    Greenberg, Steven J.
    Zivadinov, Robert
    Lee-Kwen, Peterkin
    Sharma, Jitendra
    Planter, Margaret
    Umhauer, Margaret
    Glenister, Norman
    Bakshi, Rohit
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2016, 9 (02) : 105 - 117
  • [4] Should all patients with an initial diagnosis of multiple sclerosis be treated with Beta Interferon?
    Hodgkinson, SJ
    JOURNAL OF CLINICAL NEUROSCIENCE, 2001, 8 (04) : 378 - 379
  • [5] Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis
    Rudick, Richard A.
    Polman, Chris H.
    LANCET NEUROLOGY, 2009, 8 (06): : 545 - 559
  • [6] Double dose interferon-beta-1b (500 mcg) re-establishes efficacy and lowers neutralising antibodies in patients with breakthrough of multiple sclerosis disease on standard high-dose interferon-beta therapy
    Soucy, N.
    Cardinal, K.
    Theoret, G.
    MacLean, H.
    Freedman, M. S.
    MULTIPLE SCLEROSIS, 2006, 12 : S193 - S193
  • [7] The role of interferon-beta in the management of multiple sclerosis
    不详
    EUROPEAN CYTOKINE NETWORK, 1998, 9 (03) : 336 - 336
  • [8] Should all patients with an initial diagnosis of multiple sclerosis be treated with Beta Interferon? The case against
    Macdonell, R
    JOURNAL OF CLINICAL NEUROSCIENCE, 2001, 8 (04) : 379 - 381
  • [9] Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis - The EVIDENCE study
    Schwid, SR
    Thorpe, J
    Sharief, M
    Sandberg-Wollheim, M
    Rammohan, K
    Wendt, J
    Panitch, H
    Goodin, D
    Li, D
    Chang, P
    Francis, G
    ARCHIVES OF NEUROLOGY, 2005, 62 (05) : 785 - 792
  • [10] Measurement of antibodies to interferon beta in patients with multiple sclerosis
    Pachner, AR
    ARCHIVES OF NEUROLOGY, 2001, 58 (08) : 1299 - 1300
12345